Supplementary Figure S9 from Biomarker Analysis and Treatment Dynamics Following Preoperative Ipilimumab plus Nivolumab in Locally Advanced Urothelial Cancer from the Phase IB NABUCCO Study

Treatment dynamics of CD8+TCF7+ T-cells in two responders to ipilimumab-high. a. Baseline bladder tissue stained with a multiplex immunofluorescence T-cell panel (DAPI (blue), PanCK (white), CD8 (red), TCF7 (yellow)) for responder #1 (ypT0N0) to high-dose ipilimumab plus nivolumab. b. On-treatment resected bladder tissue stained with a multiplex immunofluorescence T-cell panel for responder #1 (ypT0N0) to high-dose ipilimumab plus nivolumab; c. Baseline bladder tissue stained with a multiplex immunofluorescence T-cell panel for responder #14 (ypT0N0) to high-dose ipilimumab plus nivolumab; d. On-treatment resected bladder tissue stained with a multiplex immunofluorescence T-cell panel for responder #14 (ypT0N0) to high-dose ipilimumab plus nivolumab. The on-treatment tissue of both patients was used for single-cell RNA-sequencing to further characterize the CD8+TCF7+ cells.